Clinical Trial Update: Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating an ultra-fast BCMA/CD70 CAR-T therapy for refractory Systemic Lupus Erythematosus; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Ultra-Fast BCMA/CD70 CAR-T Therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING